info@seagull-health.com
SeagullHealth
语言:
search
new
What Are the Side Effects of Perfluorohexyl Octane Eye Drops (Miebo)?
504
Article source: Seagull Pharmacy
Nov 11, 2025

Perfluorohexyl Octane Eye Drops (Miebo) is a new dry eye treatment drug approved in the United States in 2023, with its active ingredient being 100% perfluorohexyl octane.

What Are the Side Effects of Perfluorohexyl Octane Eye Drops (Miebo)?

Common Side Effects

Blurred vision is the most common ocular adverse reaction, with an incidence rate of less than 4%.

Approximately 1-3% of patients experience conjunctival hyperemia.

These reactions are mostly transient and usually do not affect the continuation of treatment.

Watch for Severe Side Effects of Perfluorohexyl Octane Eye Drops (Miebo)

Hypersensitivity Reactions

Perfluorohexyl Octane Eye Drops are contraindicated in patients allergic to perfluorohexyl octane.

Some patients may experience allergic reactions, such as eyelid swelling, rash, or difficulty breathing.

If relevant symptoms occur after medication use, the drug must be discontinued immediately and medical attention sought.

Risks in Special Populations

Pregnant Women: Animal studies have shown that when rabbits were exposed to a dose 41 times the recommended human dose, miscarriages, decreased fetal weight, and maternal toxicity occurred. Data in humans is not yet clear, and the drug should be used only after weighing the pros and cons.

Lactating Women: It is unknown whether perfluorohexyl octane is excreted in breast milk. It is recommended to consult a doctor before making a decision on use.

Children and Elderly People: The safety of the drug in people under 18 years of age has not been established. There are no significant differences in safety or efficacy between elderly patients and younger populations.

Precautions for Using Perfluorohexyl Octane Eye Drops (Miebo)

Specifications for Contact Lens Use

Contact lenses must be removed before using the eye drops, and you should wait for at least 30 minutes after instillation before reinserting them.

The drug ingredients may be absorbed by the contact lenses, which could cause irritation or reduce the therapeutic effect.

Correct Eye Drop Instillation Steps

Unscrew the bottle cap, keep the bottle upright, and gently squeeze the bottle body.

While squeezing, invert the bottle opening and release the pressure to draw in air.

Keep the bottle in an inverted position, align the bottle opening with the eye, and squeeze again to instill the liquid.

If both eyes require treatment, repeat the above steps.

Storage and Expiration Date

Store the drug in an environment at 15℃–25℃. After opening the bottle, it can be used until the expiration date marked on the bottle.

If the liquid changes color or becomes turbid, it must be discontinued immediately.

Drug Interaction Information

No clear drug interactions have been identified so far. However, if other eye drops need to be used at the same time, the interval between uses should be no less than 5 minutes to avoid diluting or flushing out the drug.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
Precautions for Using Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a new type of semifluorinated alkane eye drops. Approved in the United States in 2023, it is specifically used to treat the signs and symptoms of dry eye dis...
How to Use Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a semifluorinated alkane ophthalmic solution. It was first approved in the United States in 2023 and is specifically used to treat the signs and symptoms of ...
Indications of Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a new ophthalmic therapeutic drug approved by the U.S. Food and Drug Administration (FDA) in 2023, providing an innovative treatment option for patients with...
How to Purchase Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a new dry eye treatment drug approved in 2023. Its unique evaporation-inhibiting effect provides a new option for patients with dry eye syndrome.How to Purch...
How to Purchase Cobenfy (KarXT)
Cobenfy (KarXT) is a new antipsychotic drug approved in 2024. Its dual mechanism of action provides a new option for patients with schizophrenia. As a strictly controlled prescription drug, standardiz...
Indications for Cobenfy (KarXT)
Cobenfy (KarXT) is an innovative oral capsule medication approved by the U.S. Food and Drug Administration (FDA) in 2024, specifically indicated for the treatment of schizophrenia in adults. This medi...
How to Use Cobenfy (KarXT)
Cobenfy (KarXT) is an oral capsule formulation composed of xanomeline (a muscarinic agonist) and trospium chloride (a muscarinic antagonist). It was first approved in the United States in 2024 for the...
Precautions for Using Cobenfy (KarXT)
Cobenfy (KarXT) is an innovative therapeutic drug for schizophrenia, approved in the United States in 2024 and specifically designed for adult patients with schizophrenia. This drug is a fixed-dose co...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved